Zimmer Biomet Holdings, Inc. (ZBH) Shares Bought by Hills Bank & Trust Co.

Hills Bank & Trust Co. increased its position in Zimmer Biomet Holdings, Inc. (NYSE:ZBH) by 5.0% during the second quarter, according to its most recent Form 13F filing with the SEC. The fund owned 11,264 shares of the medical equipment provider’s stock after buying an additional 540 shares during the period. Hills Bank & Trust Co.’s holdings in Zimmer Biomet Holdings were worth $1,447,000 as of its most recent filing with the SEC.

A number of other institutional investors also recently added to or reduced their stakes in ZBH. Chesley Taft & Associates LLC acquired a new stake in shares of Zimmer Biomet Holdings during the first quarter worth $210,000. Stock Yards Bank & Trust Co. raised its stake in shares of Zimmer Biomet Holdings by 1.0% in the first quarter. Stock Yards Bank & Trust Co. now owns 66,000 shares of the medical equipment provider’s stock worth $8,059,000 after buying an additional 637 shares during the last quarter. Creative Planning raised its stake in shares of Zimmer Biomet Holdings by 26.2% in the first quarter. Creative Planning now owns 15,334 shares of the medical equipment provider’s stock worth $1,872,000 after buying an additional 3,184 shares during the last quarter. Raymond James Trust N.A. raised its stake in shares of Zimmer Biomet Holdings by 0.3% in the first quarter. Raymond James Trust N.A. now owns 8,985 shares of the medical equipment provider’s stock worth $1,097,000 after buying an additional 31 shares during the last quarter. Finally, Indiana Trust & Investment Management CO acquired a new stake in shares of Zimmer Biomet Holdings during the first quarter worth $248,000. 83.62% of the stock is owned by institutional investors and hedge funds.

Zimmer Biomet Holdings, Inc. (ZBH) opened at 111.70 on Friday. Zimmer Biomet Holdings, Inc. has a one year low of $95.63 and a one year high of $133.49. The company has a market capitalization of $22.59 billion, a price-to-earnings ratio of 31.81 and a beta of 1.20. The firm has a 50-day moving average of $124.93 and a 200 day moving average of $121.26.

Zimmer Biomet Holdings (NYSE:ZBH) last released its earnings results on Thursday, July 27th. The medical equipment provider reported $2.08 earnings per share for the quarter, missing the consensus estimate of $2.10 by $0.02. Zimmer Biomet Holdings had a return on equity of 16.70% and a net margin of 9.12%. The business had revenue of $1.95 billion for the quarter, compared to the consensus estimate of $1.95 billion. During the same quarter last year, the business posted $2.02 earnings per share. The firm’s revenue for the quarter was up 1.1% compared to the same quarter last year. Equities research analysts predict that Zimmer Biomet Holdings, Inc. will post $8.24 earnings per share for the current fiscal year.

The firm also recently announced a quarterly dividend, which will be paid on Friday, October 27th. Stockholders of record on Friday, September 22nd will be given a dividend of $0.24 per share. The ex-dividend date of this dividend is Thursday, September 21st. This represents a $0.96 annualized dividend and a dividend yield of 0.86%. Zimmer Biomet Holdings’s dividend payout ratio (DPR) is 27.59%.

ILLEGAL ACTIVITY NOTICE: “Zimmer Biomet Holdings, Inc. (ZBH) Shares Bought by Hills Bank & Trust Co.” was first posted by Community Financial News and is the property of of Community Financial News. If you are reading this report on another domain, it was illegally stolen and reposted in violation of U.S. and international trademark & copyright laws. The original version of this report can be read at https://www.com-unik.info/2017/08/12/hills-bank-trust-co-has-1-45-million-stake-in-zimmer-biomet-holdings-inc-zbh-updated-updated.html.

ZBH has been the subject of a number of recent research reports. Goldman Sachs Group, Inc. (The) initiated coverage on shares of Zimmer Biomet Holdings in a report on Tuesday, May 16th. They issued a “sell” rating and a $92.00 price objective for the company. Canaccord Genuity restated a “buy” rating on shares of Zimmer Biomet Holdings in a report on Friday, April 28th. Wells Fargo & Company lowered shares of Zimmer Biomet Holdings from an “outperform” rating to a “market perform” rating in a report on Friday, April 28th. Zacks Investment Research lowered shares of Zimmer Biomet Holdings from a “hold” rating to a “strong sell” rating in a report on Tuesday. Finally, Morgan Stanley boosted their price objective on shares of Zimmer Biomet Holdings from $137.00 to $150.00 and gave the stock an “overweight” rating in a report on Monday, July 17th. Four equities research analysts have rated the stock with a sell rating, seven have given a hold rating, thirteen have given a buy rating and one has given a strong buy rating to the stock. Zimmer Biomet Holdings presently has an average rating of “Hold” and an average price target of $136.90.

In related news, insider Sang Yi sold 17,731 shares of Zimmer Biomet Holdings stock in a transaction dated Monday, June 12th. The stock was sold at an average price of $124.56, for a total value of $2,208,573.36. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available through this hyperlink. Also, VP Tony W. Collins sold 16,986 shares of Zimmer Biomet Holdings stock in a transaction dated Monday, July 31st. The shares were sold at an average price of $121.74, for a total value of $2,067,875.64. The disclosure for this sale can be found here. 1.07% of the stock is currently owned by company insiders.

Zimmer Biomet Holdings Company Profile

Zimmer Biomet Holdings, Inc is engaged in designing, manufacturing and marketing of orthopedic reconstructive products; sports medicine, biologics, extremities and trauma products; office-based technologies; spine, craniomaxillofacial and thoracic products; dental implants, and related surgical products.

Institutional Ownership by Quarter for Zimmer Biomet Holdings (NYSE:ZBH)

What are top analysts saying about Zimmer Biomet Holdings Inc.? - Enter your email address in the form below to receive our free daily email newsletter that contains the latest headlines and analysts' recommendations for for Zimmer Biomet Holdings Inc. and related companies.

Comments

Leave a Reply


share news on Facebook
tweet this investment news
share on linkedin
share on StockTwits
share on Google Plus
share on reddit